Migrium5 mg

Migrium is a selective calcium channel blocker with well-established (guideline-supported) uses in:

• Prophylaxis of migraine (with or without aura) in patients with frequent and/or severe attacks who have not responded adequately to other measures. It is not intended for treating an acute migraine attack.
• Symptomatic treatment of vertigo of vestibular origin (e.g., Meniere's disease-related vertigo, vestibular dysfunction).

It has also been used, with more limited or regional evidence, for motion sickness prophylaxis and as adjunctive therapy in peripheral vascular disease and refractory epilepsy; such uses should follow specific prescriber guidance.

Each tablet contains Flunarizine (as flunarizine hydrochloride/dihydrochloride) as the active ingredient, commonly available in strengths of 5 mg and 10 mg for oral administration, along with standard pharmaceutical excipients.

Migrium is a diphenylmethylpiperazine derivative that acts as a selective calcium channel blocker. It also exhibits antihistaminic properties. It is used mainly in the prophylaxis of migraine and in the symptomatic management of vertigo of vestibular origin. Migrium is not approved by the US FDA; its use is supported by regulatory labeling and clinical guidance in Europe, Canada, and various Asian markets, including Bangladesh, where it is available as an oral tablet.

Anti-migraine agent / Calcium channel blocker used for migraine prophylaxis and vestibular vertigo.

Flunarizine is a selective calcium channel antagonist (calcium overload blocker) that inhibits excessive transmembrane influx of calcium ions into cells without significantly affecting normal calcium homeostasis. This action is believed to stabilize vascular tone and neuronal excitability relevant to migraine and vestibular disorders. Flunarizine also has antihistaminic (H1) activity and central sedative effects, and it is highly bound to plasma proteins (about 99%). It has a very long elimination half-life (on the order of several weeks), which underlies its cyclical dosing regimen with drug-free intervals.

Migrium tablets are taken orally, generally once daily at bedtime because of associated drowsiness. Tablets may be taken with or without food, swallowed with water, and should not be chewed or crushed unless directed. Consistent timing of the dose is recommended.

Migrium has clinically significant interactions with:

• CNS depressants (sedatives, hypnotics, tranquilizers, other antipsychotics) and alcohol — concurrent use may intensify sedation and drowsiness.
• Other drugs associated with extrapyramidal or parkinsonian effects (e.g., certain antipsychotics/neuroleptics) — combined use may increase the risk of movement disorders.
• Hepatic enzyme-inducing drugs such as carbamazepine and phenytoin — may lower plasma levels of Migrium, potentially reducing effectiveness.

Inform the prescriber of all other medicines being used before starting Migrium.

Common side effects of Migrium include:

• Drowsiness/sedation and fatigue, particularly at the start of treatment.
• Increased appetite and weight gain.
• Gastrointestinal upset (nausea, heartburn, dry mouth).
• Headache, insomnia, or anxiety in some patients.

Less common but clinically important effects include depression and extrapyramidal symptoms (tremor, rigidity, bradykinesia, akathisia, orofacial dyskinesia) — see Precautions and Warnings and Duration of Treatment for details, as these are linked to prolonged use and are more frequent in elderly patients. Rarely, galactorrhea, muscle aches, or skin rash may occur.

The safety of Migrium in pregnancy has not been established. It should generally be avoided during pregnancy and used only if the anticipated benefit clearly outweighs potential risk, at the prescriber's judgment.

Migrium is excreted into breast milk, at times at concentrations higher than plasma levels; it is generally not recommended during breastfeeding. A decision to discontinue nursing or discontinue the drug should be made considering the importance of treatment to the mother.

Migrium requires caution regarding:

• Depression: May cause or unmask depression, particularly in patients with a personal or family history; the drug should be stopped if depressive symptoms occur. Contraindicated in those with a prior history of depression.
• Extrapyramidal symptoms/parkinsonism: May cause tremor, rigidity, bradykinesia, or other movement disorders, especially with prolonged use and in elderly patients; these may take time to resolve after stopping. Contraindicated in patients with Parkinson's disease or other extrapyramidal disorders.
• Sedation and drowsiness: Common, especially early in treatment; patients should use caution when driving or operating machinery, and avoid alcohol or other CNS depressants.
• Weight gain: May occur due to increased appetite; monitor and counsel patients accordingly.
• Elderly patients: Not generally recommended unless clearly indicated, because of a higher risk of sedation and extrapyramidal effects; a lower dose is used if prescribed.
• Duration of use: Should be limited and periodically reassessed rather than used indefinitely (see Duration of Treatment).

Migrium is not intended for treating an acute migraine attack.

Overdose with Migrium may present with excessive sedation, confusion, agitation, and tachycardia, reflecting an extension of its known pharmacologic effects. There is no specific antidote. Management is supportive and symptomatic, and may include measures to limit further drug absorption (such as activated charcoal, if appropriate and administered promptly) along with monitoring of vital signs and cardiac/neurologic status. Anyone suspected of having taken an overdose of Migrium should seek prompt medical attention or contact a poison control service.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: Use of Migrium is not generally recommended in elderly patients unless clearly indicated, given a higher risk of sedation, extrapyramidal symptoms, and depression; when used, a lower starting dose (e.g., 5 mg daily) is typical and close monitoring is advised.

Renal/Hepatic impairment: Use with caution; specific dose adjustment data are limited, so clinical judgment and monitoring are advised.

Pediatric patients: See Pediatric Uses.

Pregnancy and lactation: See Pregnancy and Lactation section.

Migrium is typically used in defined treatment courses rather than as continuous, indefinite therapy. For migraine prophylaxis, response is usually assessed after about 2–3 months; if there is no adequate benefit, treatment is generally discontinued. When continued, many regimens limit continuous use to a maximum of approximately 6 months at a time (sometimes with scheduled medicine-free days), after which the need for ongoing therapy is reassessed by the prescriber. This limit reflects the risk of Migrium-associated depression and extrapyramidal symptoms/parkinsonism (tremor, rigidity, bradykinesia) with prolonged use, effects that are more common in elderly patients and that may persist for a period after the drug is stopped. Any resumption of therapy after a treatment-free interval should follow the prescriber's specific instructions.

Selective calcium channel blocker (diphenylmethylpiperazine derivative) with antihistaminic properties; classified as an anti-migraine/anti-vertigo agent.

Flunarizine selectively inhibits excessive calcium influx across cell membranes, protecting cells (including neurons and vascular smooth muscle) from calcium overload without disrupting normal calcium-dependent physiological processes. This calcium channel-blocking activity, along with its antihistaminic and central sedative properties, is thought to underlie its effects in reducing the frequency of migraine attacks and improving symptoms of vestibular vertigo.

Data on Migrium use in children are limited, and many regulatory labels have not established a specific pediatric indication. Where used (for example, for vertigo or as adjunctive therapy in select cases under specialist supervision), conservative, weight-based low dosing is applied and only under close medical supervision. Migrium should not be used in children outside specific specialist guidance, and the same warnings regarding sedation, depression, and extrapyramidal symptoms apply.